Home・Список акций・Genmab A-S

Genmab A-S

Закрыт

2,662 1.29

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2590

Макс.

2634

Ключевые показатели
By Trading Economics
Доход	243M 295M
Продажи	259M 1.2B
P/E Средняя по отрасли	31.352 49.241
Прибыль на акцию	34.85
Рентабельность продаж	25.541
Сотрудники	3,119
EBITDA	216M 431M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	-1.49% downside

Дивиденды
By Acuity
Следующий отчет о доходах	5 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	43B 156B
Предыдущая цена открытия	2660.71
Предыдущая цена закрытия	2662

Genmab A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 окт. 2026 г., 23:56 UTC

Daily Journal Corp shares advanced in after-market trading, settling at a notable gain.

22 окт. 2026 г., 23:56 UTC

Zimmer Biomet Holdings, Inc. shares declined modestly in after-market trading, retracing from a brief peak earlier in the session.

22 окт. 2026 г., 23:56 UTC

PENN Entertainment Inc is trading higher in after-market hours, significantly above its 20-day moving average and near the upper end of its one-month trading range.

22 окт. 2026 г., 23:56 UTC

XP Inc shares are experiencing a modest decline in after-market hours, marking three consecutive daily decreases while remaining above their 20-day moving average.

22 окт. 2026 г., 23:56 UTC

Correlated Moves

Routine after-market trading shows little change since Thursday's close.

22 окт. 2026 г., 23:56 UTC

CRISPR Therapeutics AG is trading slightly higher in after-market hours, reflecting a modest increase since Thursday's close while remaining below its 20-day moving average.

22 окт. 2026 г., 23:56 UTC

Hess Midstream LP is trading modestly higher in after-market hours, recovering from an earlier low while remaining below its 20-day moving average.

22 окт. 2026 г., 23:56 UTC

Old Dominion Freight Line Inc is trading roughly flat in after-market hours, maintaining a position just above its Thursday close.

22 окт. 2026 г., 23:56 UTC

Agree Realty Corp shares are trading lower in after-market hours, with a cumulative return declining from a low, remaining above its 20-day moving average.

22 окт. 2026 г., 23:56 UTC

McCormick & Company Inc shares are trading modestly lower in after-market hours, declining from earlier in the session but remaining above its 20-day moving average.

22 окт. 2026 г., 23:52 UTC

Macro News

Natural gas prices are higher amid rising tensions in the Middle East, with concerns about military conflicts potentially impacting global oil and gas markets.

22 окт. 2026 г., 23:52 UTC

Japan's Inflation Rate Rises to 2.1% in September, Aligning with Expectations and Indicating Economic Stability

22 окт. 2026 г., 23:52 UTC

Japan's Core Inflation Rate Rises to 2.1%, Meeting Expectations and Indicating Economic Stability Amid Global Pressures

22 окт. 2026 г., 23:52 UTC

UK Consumer Confidence Plummets to -24.0, Signaling Economic Pessimism Amid Rising Inflation and Geopolitical Tensions

22 окт. 2026 г., 23:52 UTC

U.S. Consumer Sentiment Expected to Decline to 46.3 Amid Economic Concerns Ahead of Midterm Elections

22 окт. 2026 г., 23:52 UTC

Australia's Inflation Rate Release on October 28 Sparks Market Speculation of Interest Rate Hikes Amid Rising Global Pressures.

22 окт. 2026 г., 23:52 UTC

Australia's Core Inflation Rate Expected to Rise, Heightening Speculation of November Interest Rate Hike Amidst Oil Price Pressures.

22 окт. 2026 г., 23:52 UTC

Japan's Industrial Production Data Release on October 29 Faces Cautious Market Sentiment Amid Recent Declines and Economic Uncertainties.

22 окт. 2026 г., 23:52 UTC

Japan's Retail Sales Data Release on October 29 Sparks Caution Amidst Economic Slowdown and Trade Deficits.

22 окт. 2026 г., 23:52 UTC

Social Media

Walmart Inc shares traded higher in after-market hours, gaining ground since Thursday's close, with users on X discussing potential upward movement based on chart patterns.

22 окт. 2026 г., 23:51 UTC

Regeneron Pharmaceuticals Inc is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

22 окт. 2026 г., 23:51 UTC

DTE Energy Co shares are trading modestly lower in after-market hours, reflecting a slight decline since Thursday's close while remaining above the 20-day moving average.

22 окт. 2026 г., 23:51 UTC

In after-market trading, Church & Dwight Co Inc is modestly lower, retracing from earlier gains and declining below Thursday's close.

22 окт. 2026 г., 23:51 UTC

Penumbra Inc shares are trading modestly higher in after-market hours, recovering from an earlier dip and reaching a high point above its 20-day moving average.

22 окт. 2026 г., 23:51 UTC

Figs Inc shares advanced in after-market trading, continuing an upward trajectory since Thursday's close and finishing higher for five consecutive sessions.

22 окт. 2026 г., 23:51 UTC

Motorola Solutions Inc. is trading modestly higher in after-market hours, marking four consecutive daily gains and remaining above its 20-day moving average.

22 окт. 2026 г., 23:51 UTC

Sirius XM Holdings Inc is trading modestly higher in after-market hours, recovering from a low point immediately after the market closed.

22 окт. 2026 г., 23:51 UTC

Align Technology Inc is trading modestly lower in after-market hours, having dipped to its lowest point.

22 окт. 2026 г., 23:51 UTC

Correlated Moves

American Superconductor Corp shares are trading lower in after-market hours, marking their lowest point since Thursday's close following a brief peak.

22 окт. 2026 г., 23:51 UTC

Johnson & Johnson shares traded modestly lower during after-market hours on Thursday, breaking a recent trend of higher daily closes.

Сравнение c конкурентами

Изменение цены

Genmab A-S Прогноз

Целевая цена

By TipRanks

-1.49% падение

Прогноз на 12 месяцев

Средняя 2,493.35 DKK -1.49%

Максимум 3,320 DKK

Минимум 308.417 DKK

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Genmab A-S на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям Genmab A-S – Данные за последние 3 месяца.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.